DIAGNOS Positioned for Growth as CARA Advances Toward Major Regulatory Approvals DIAGNOS Inc. (TSXV: ADK) is a medical AI company that develops and commercializes CARA (Computer Assisted Retinal Analysis), a cloud-based, AI-powered software platform for the early detection of retinal diseases and systemic conditions. CARA integrates with standard fundus cameras via a secure internet connection to deliver real-time pathology detection using proprietary deep-learning algorithms. The current version of CARA can detect early signs of age-related macular degeneration (AMD) and diabetic retinopathy. The platform is used by optometrists, optical chains, and medical institutions, and has cumulatively assessed 400,000 patients across 140 clinics in 16 countries. 

Deposits Drive Momentum into Golf Season: NWTG recently reported Q1:26 financial results that were modestly below expectations, reflecting a seasonally softer quarter and operational investments made to enhance manufacturing capacity. Encouragingly, customer deposits and open orders increased meaningfully during Q1, supporting our view that demand for NWTG’s products remains strong heading into the golf season. 

2026 Return to Growth Likely Arrives: Long-term accomplished founder and management have shepherded SBC from a solo clinic in 2000 to a global cosmetic treatment center franchiser and cash generation machine with little debt. Near-term revenue growth decline in 2025 on pricing pressures (reflecting increased market competition pressure) appears to now be completed. Accordingly, the Company should likely begin to grow anew going forward with additional prospects, global and Japanese M&A targets, and AI and Longevity initiatives. The recent small founder share sale is positive for trading liquidity (i.e., management remains confident in operating strategy). SBC 

Innovative Golf Equipment Manufacturer has Strong Growth Potential, Initiate with a Buy-Emerging Rating. Newton Golf Company, Inc. is an innovative, technology-forward golf product manufacturer that has exhibited strong revenue growth over the last couple of fiscal years. Driven by strong momentum in the golf shaft market, with adoption increasing on professional tours, NWTG has strong revenue growth prospects that we believe will push the Company to positive EBITDA in the back half of 2027. 

Specialty-Financed Licensing Deal Delivers Strong De-Risking: OSRH executed an $815 million definitive exclusive license agreement with BCME for global development, commercialization, and out-licensing of VXM01. The agreement's specialty-financed structure – increasingly common among development-stage assets – is consistent with market trends and represents a de-risking milestone (e.g., OSRH is slated to receive at least $15 million cash within six months, even in a worst-case scenario). This important step, combined with impressive named global corporate partners at Woori IO (i.e., noninvasive blood glucose monitoring) bodes well. Shares experienced volatility in the wake of the announcement, creating a potential floor. If OSRH now grows 4PL, profitably integrates Woori IO, and successfully develops drug candidates, price upside is substantial.